Body image and psychosocial effects in women after treatment of breast cancer: A prospective study.

Body image Breast cancer Health-related quality of life Return to work

Journal

American journal of surgery
ISSN: 1879-1883
Titre abrégé: Am J Surg
Pays: United States
ID NLM: 0370473

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 03 07 2024
revised: 30 07 2024
accepted: 12 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

To explore treatment-related, socio-economic, and psychological factors influencing body image and return to work. 137 patients participated in the study. A questionnaire was completed before surgery and at 1-year follow-up, where patients were also interviewed in person with questions modified from the Body Image Scale and the sexual adjustment scale as well as questions about their work status. There was a significant decline in body image score from baseline to 1-year follow-up related to younger age, more extensive surgery and post-surgery treatments. Treatment with adjuvant chemotherapy was associated with a lower rating on ability to work in relation to mental requirements and later return to work. Higher anxiety scores at baseline were associated with both a decline in body image and a delay in return to work. Breast cancer surgery can affect body image and especially adjuvant chemotherapy seems to affect work ability. However, personal characteristics are also involved and thus should be considered when planning for treatment of breast cancer.

Identifiants

pubmed: 39208502
pii: S0002-9610(24)00447-1
doi: 10.1016/j.amjsurg.2024.115895
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115895

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Nanna Brix Finnerup has received consultancy fees from PharmNovo, Vertex, NeuroPN, Saniona, Nanobiotix, and Neurvati, and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics outside the submitted work. She has received grants from IMI2PainCare an EU IMI 2 (Innovative medicines initiative) public-private consortium and the companies involved are: Grunenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. The other authors declare no conflicts of interest.

Auteurs

Inge Scheel Andersen (IS)

Department of Breast Surgery, Esbjerg Hospital, Finsesgade 35, 6700, Esbjerg, Denmark. Electronic address: inge.scheel@dadlnet.dk.

Ditte Mee Ran Jensen (DMR)

Department of Breast Surgery, Regional Hospital Viborg, Heibergs Alle 5A, 8800, Viborg, Denmark. Electronic address: dijese@rm.dk.

Kasper Grosen (K)

Research Centre for Health and Welfare Technology, VIA University College, Hedeager 2, 8200, Aarhus N, Denmark. Electronic address: kasp@via.dk.

Kristine Tang Bennedsgaard (KT)

Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. Electronic address: krbenn@clin.au.dk.

Lise Ventzel (L)

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Beriderbakken 4, 7100, Vejle, Denmark. Electronic address: lise.ventzel@rsyd.dk.

Nanna Brix Finnerup (NB)

Danish Pain Research Center, Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. Electronic address: finnerup@clin.au.dk.

Classifications MeSH